A Phase 2 interventional study of Calcium Chloride and Sodium chloride 0.9% in Heart Arrest, Out-Of-Hospital, sponsored by Lars Wiuff Andersen. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-25.
Sponsored by Lars Wiuff Andersen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark — 7 open to participants now, 8 under way, 2 of them phase 3. Out-of-Hospital Cardiac Arrest · Denmark.
Among the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, this one is the 13th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2020, is one of 4 in phase 2, and was the 18th registered.
314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.
Browse Out-of-Hospital Cardiac Arrest studies →7 of the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark are open now. Recruiting first, the newest first:
Lars Wiuff Andersen · Sites in Denmark
Ages 18+
Christian Hassager · Sites in Denmark
Ages 18+
Emergency Medical Services, Capital Region, Denmark · Sites in Denmark
Ages 8+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Bo Gregers Winkel · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 397 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.
Median enrollment 376 across the 26 interventional studies, 900 across the 12 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 38 have an industry lead sponsor. The 10 most frequent:
Lars Wiuff Andersen is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Lars Wiuff Andersen has 2 studies filed under Out-of-Hospital Cardiac Arrest — fewer than ten, so there is no comparison to draw.
3 of the studies in Out-of-Hospital Cardiac Arrest with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05895838Phase 3Christian HassagerThe Danish Out-of-Hospital Cardiac Arrest Study | 2027-09 |
| NCT04446585Emergency Medical Services, Capital Region, DenmarkCardiac Arrest in Residential Areas With Mobile First-responder Activation | 2027-01 |
| NCT06744361Christian HassagerKetamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of calcium during adult out-of-hospital cardiac arrest. 430 adult patients with out-of-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. The primary outcome is sustained return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention will consist of 5 mmol (10 mL ampoule) of calcium chloride (CaCl2) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.
Drug: Calcium Chloride
The placebo will consist of 10 mL of 9 mg/mL sodium chloride (NaCl, "normal saline") administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.
Drug: Sodium chloride 0.9%
Calcium chloride 5 mmol
Also known as: CaCl2
Placebo
Number of Participants With Sustained Return of Spontaneous Circulation
Palpable pulses or other signs of circulation without a need for chest compressions lasting at least 20 minutes.
Time frame: Before or after hospital arrival (up to 2 hours after the cardiac arrest)
Number of Participants With 30-day Survival
Time frame: 30 days after the cardiac arrest
Number of Participants With 30-day Favorable Neurological Outcome
Neurological outcome will be assessed with the modified Rankin Scale (mRS) which is a scale from 0 to 6 assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes. The scale will will be dichotomized as favorable (mRS 0-3) vs. unfavorable (mRS 4-6).
Time frame: 30 days after the cardiac arrest
| Milestone | Calcium | Placebo |
|---|---|---|
| Started | 197 | 200 |
| Completed | 197 | 200 |
| Not completed | 0 | 0 |
Palpable pulses or other signs of circulation without a need for chest compressions lasting at least 20 minutes.
| Participants | Calcium | Placebo |
|---|---|---|
| Number of Participants With Sustained Return of Spontaneous Circulation | 37 | 53 |
| Participants | Calcium | Placebo |
|---|---|---|
| Number of Participants With 30-day Survival | 10 | 18 |
Neurological outcome will be assessed with the modified Rankin Scale (mRS) which is a scale from 0 to 6 assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes. The scale will will be dichotomized as favorable (mRS 0-3) vs. unfavorable (mRS 4-6).
| Participants | Calcium | Placebo |
|---|---|---|
| Number of Participants With 30-day Favorable Neurological Outcome | 7 | 15 |
Collected over 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Calcium | 183/193 (94.8%) | — | — |
| Placebo | 180/198 (90.9%) | — | — |
All patients received the trial drug and meeting all inclusion criteria and none of the exclusion criteria.
| Age, Continuous(years) | Calcium | Placebo | Total |
|---|---|---|---|
| Mean | 67 ± 14 | 69 ± 14 | 68 ± 14 |
| Sex: Female, Male(Participants) | Calcium | Placebo | Total |
|---|---|---|---|
| Female | 62 | 52 | 114 |
| Male | 131 | 146 | 277 |
| Race and Ethnicity Not Collected(Participants) | Calcium | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Six months after the publication of the last results, all deidentified individual patient data will be made available for data sharing. Procedures, including re-coding of key variables, will be put in place to allow for complete deidentification of the data. Data will be completely anonymized according to Danish law.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Six months after the publication of the last results
Access criteria: Data will be available for any research purpose to all interested parties who have approval from an independent review committee and who have a methodological sound proposal as determined by the steering committee of the current trial. Only the methodological qualities and not the purpose or objective of the proposal will be considered.
Ran from Jan 2020 to primary completion in Apr 2021, 14 months.
Results were first posted in Feb 2022, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Calcium Chloride
Out-of-Hospital Cardiac Arrest →
Lars Wiuff Andersen